McCluskie M J, Krieg A M
Coley Pharmaceutical Group, Inc., 93 Worcester Street, Suite 101, Wellesley, MA 02481, USA.
Curr Top Microbiol Immunol. 2006;311:155-78. doi: 10.1007/3-540-32636-7_6.
The adaptive immune system-with its remarkable ability to generate antigen-specific antibodies and T lymphocytes against pathogens never before "seen" by an organism-is one of the marvels of evolution. However, to generate these responses, the adaptive immune system requires activation by the innate immune system. Toll-like receptors (TLRs) are perhaps the best-understood family of innate immune receptors for detecting infections and stimulating adaptive immune responses. TLR9 appears to have evolved to recognize infections by a subtle structural difference between eukaryotic and prokaryotic/viral DNA; only the former frequently methylates CpG dinucleotides. Used as vaccine adjuvants, synthetic oligodeoxynucleotide (ODN) ligands for TLR9--CpG ODN--greatly enhance the speed and strength of the immune responses to vaccination.
适应性免疫系统能够产生针对生物体从未“见过”的病原体的抗原特异性抗体和T淋巴细胞,其非凡能力是进化的奇迹之一。然而,为了产生这些反应,适应性免疫系统需要由先天性免疫系统激活。Toll样受体(TLR)可能是最广为人知的先天性免疫受体家族,用于检测感染并刺激适应性免疫反应。TLR9似乎已经进化到通过真核生物与原核生物/病毒DNA之间的细微结构差异来识别感染;只有前者经常使CpG二核苷酸甲基化。作为疫苗佐剂使用的TLR9合成寡脱氧核苷酸(ODN)配体——CpG ODN——极大地提高了疫苗接种免疫反应的速度和强度。